Barrick Mining Corporation Stock Price, News & Analysis

Barrick (NYSE:B) announced on November 24, 2025 that it has reached an agreement with the Government of the Republic of Mali to end disputes over the Loulo and Gounkoto mines.

Under the agreement, all charges against Barrick, its affiliates and employees will be dropped, the legal steps to secure the release of four detained Barrick employees will be taken, and the provisional administration of the Loulo-Gounkoto complex will be terminated, returning operational control to Barrick. Barrick subsidiaries will also withdraw ICSID arbitration claims, enabling a constructive path forward.

Crawford & Company (NYSE: CRD-A and CRD-B) announced a leadership transition: CEO Rohit Verma will step down effective December 31, 2025, and CFO W. Bruce Swain Jr. will become interim president & CEO and board member effective January 1, 2026. Holly Boudreau will succeed Swain as CFO effective January 1, 2026. Swain brings more than 30 years at Crawford and will focus on executing strategic plans and empowering employees. Verma served as CEO since May 2020 and joined Crawford in 2017. The company describes the transition as occurring from a position of financial strength with a global leadership team in place.

BioArctic (Nasdaq: B) announced that partner Eisai will present new data on lecanemab (Leqembi) at the CTAD conference in San Diego, Dec 1–4, 2025.

Presentations cover long‑term treatment analyses, estimated time savings over 10 years, safety and pharmacokinetics for a subcutaneous initiation option, effects on soluble Aβ protofibrils, and real‑world registry findings including ALZ‑NET and a Japanese post‑marketing study.

BioArctic (NASDAQ: B) partner Eisai received MHRA approval in the United Kingdom for Leqembi (lecanemab) as a once-every-four-weeks IV maintenance treatment for early Alzheimer’s disease on November 14, 2025.

After an initial 18-month induction of 10 mg/kg every two weeks, patients may be transitioned to 10 mg/kg every four weeks or remain on the two-week schedule. Leqembi previously received a UK approval in August 2024 for treatment of MCI and mild dementia due to Alzheimer’s in ApoE ε4 heterozygotes and non-carriers. BioArctic and Eisai are preparing joint commercialization in the Nordic region, where BioArctic holds commercialization rights.

Inertial Sense (B) agreed to be acquired by Hexagon AB (HEXA B), strengthening Hexagon’s assured Positioning, Navigation, and Timing (PNT) capabilities for autonomy, aerospace, and defense.

Under the agreement, Inertial Sense will join Hexagon’s Autonomous Solutions business area and continue operations there. Inertial Sense has shipped over 30,000 navigation systems worldwide and provides centimeter-level accuracy in compact GNSS+INS products. The transaction is expected to close in the first half of 2026, subject to customary regulatory approvals and closing conditions. Financial terms were not disclosed.

B (Barrick) reported Q3 2025 results on Nov 10, 2025: revenue of $4.1B, gold production of 829,000 oz and copper production of 55,000 t. The company delivered record quarterly operating cash flow of $2.4B (+82% vs Q2) and free cash flow of $1.5B (+274% vs Q2). Net earnings were $1.3B ($0.76/share) and adjusted net earnings were $982M ($0.58/share).

The Board raised the base quarterly dividend 25% to $0.125/share and approved a total $0.175 per-share payout this quarter, expanded the buyback program by $500M (YTD repurchases $1.0B), and reiterated full-year 2025 guidance.

Barrick (NYSE:B) announced on November 10, 2025 that its Board approved a $500 million increase to the existing share repurchase program.

In February 2025 the Board authorized repurchases up to $1.0 billion over 12 months; Barrick had repurchased $1.0 billion of shares as of September 30, 2025. The additional $500 million allows for potential further repurchases over the remaining term of the program. Repurchases may occur on public U.S. markets, including the NYSE, and by other SEC‑permitted methods. The Company said actual timing and amounts will depend on financial performance, cash flow availability, capital needs, other shareholder returns, and debt reduction, and that the program may be suspended at any time. The Board will consider any 2026 program in February 2026.

B (Barrick) raised its quarterly base dividend by 25% to $0.125 per share and declared an enhanced Q3 2025 dividend of $0.175 per share (including a $0.05 performance dividend). The Q3 dividend is payable on December 15, 2025 to holders of record on November 28, 2025. Barrick repurchased approximately 18.60 million shares in Q3 and 39.79 million shares year-to-date under the 2025 buyback program, representing about 2.3% of issued shares, for total cash of $1.0 billion (including $589 million in Q3). The company updated its Performance Dividend Policy showing tiered performance payments up to $0.15 per quarter, producing a maximum quarterly total of $0.275 per share.

Cereno Scientific (B) submitted the clinical trial protocol for a planned global Phase IIb study of CS1 in pulmonary arterial hypertension (PAH) to the U.S. FDA on Nov 10, 2025. The submission follows FDA Type C meeting feedback and aims to advance CS1—an oral HDAC inhibitor that targets PAH via epigenetic modulation—after Phase IIa showed favorable safety, tolerability and encouraging efficacy signals (reverse vascular remodeling, improved right heart function, better patient quality of life). The Phase IIb is designed as a global, multicenter, placebo-controlled trial run with an international CRO. Cereno expects the FDA's standard 30-day review and plans to start the trial in H1 2026.